Printer Friendly
The Free Library
14,497,195 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Sustiva: revised drug-interaction information.


On January 31 the FDA announced that the Sustiva (efavirenz) package insert had been changed "to include drug-drug interaction information regarding coadministration of efavirenz with rifampin, diltiazem, itraconazole itraconazole /it·ra·co·na·zole/ (it?rah-kon´ah-zol) a triazoleantifungal used in a variety of infections.

it·ra·con·a·zole
n.
, voriconazole, atorvastatin atorvastatin /ator·va·stat·in/ (ah-tor?vah-stat´in) an antihyperlipidemic agent that acts by inhibiting cholesterol synthesis, used as the calcium salt in the treatment of hypercholesterolemia and other forms of dyslipidemia. , pravastatin pravastatin /prav·a·stat·in/ (prav´ah-stat?in) an antihyperlipidemic agent that acts by inhibiting cholesterol synthesis, used as the sodium salt in the treatment of hypercholesterolemia and other forms of dyslipidemia and to lower the , simvastatin, pimozide pimozide /pi·mo·zide/ an antipsychotic and antidyskinetic agent used in the treatment of Gilles de la Tourette's syndrome.

pim·o·zide
n.
 and bepridil."

The complete list of changes is at http://www.fda.gov/oashi/aids/listserve/listserve2007.html#13107

And the complete, revised prescribing information for physicians (and other information for patients) is at http://www.sustiva.com. (Click "Full U.S. Prescribing Information" to download a PDF file--and change the ending of the file name from .pl to .pdf is necessary.)
COPYRIGHT 2006 John S. James
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:AIDS Treatment News
Date:Nov 1, 2006
Words:95
Previous Article:FUZEON: avoiding injection-site reactions.
Next Article:Prisoner death rate very high immediately after release.
Topics:



Related Articles
ICAAC clinical trials review available.(Inter-Science Conference on Antimicrobial Agents and Chemotherapy)(Brief Article)
Abacavir arm stopped in clinical trial.
HIV drugs approved as of August 2003.
TMC125: important one-year trial now recruiting in U.S.
New fixed-dose once-a-day starting regimens: interview with Cal Cohen, M.D.(Interview)
Warning on two specific 3-drug regimens: Viread + Videx + either Sustiva or Viramune.(Brief Article)
Weekend treatment interruptions for certain well-controlled patients: interview with Cal Cohen, M.D.(Interview)
Four antiretrovirals reduced to three after 48 weeks.(Brief Article)
Therapeutic and diagnostic advances in the HAART era.(Essays)
Cocktail all in one: ten years after the introduction of the AIDS cocktail, many lives have been saved, but some problems still persist. Will a new...

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles